Skip to main content

Table 4 WHO classification: OS of patients with MDS or AML receiving azacitidine front-line

From: Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications

WHO diagnosis

n

Median OS, mo

95 % CI, mo

p value

AML30+

AML20–30

MDS-RAEB-II

MDS-RAEB-I

111

79

96

53

10.9

13.1

18.9

23.7

7.5–14.3

9.8–16.5

12.7–25.1

14.4–33.0

<0.001a

AML30+

AML20–30

111

79

10.9

13.1

7.5–14.3

9.8–16.5

0.238

AML20–30

MDS-RAEB-II

79

96

13.1

18.9

9.8–16.5

12.7–25.1

0.010b

MDS-RAEB-II

MDS-RAEB-I

96

53

18.9

23.7

12.7–25.1

14.4–33.0

0.302

  1. aHR = 1.292; 95 % CI 1.168, 1.430
  2. bHR = 1.645; 95 % CI 1.123, 2.409